<DOC>
	<DOCNO>NCT00095680</DOCNO>
	<brief_summary>The main objective study ass long-term effectiveness SCIO-469 monotherapy , combination bortezomib relapse , refractory patient multiple myeloma ( MM ) previously demonstrate clinical benefit Scios B003 study .</brief_summary>
	<brief_title>Extension Study Efficacy Safety Oral SCIO-469 Relapsed , Refractory Patients With Multiple Myeloma</brief_title>
	<detailed_description>The main objective study ass long-term efficacy SCIO-469 monotherapy , combination bortezomib relapse , refractory patient multiple myeloma ( MM ) previously demonstrate clinical benefit Scios B003 study . Patients take mouth two capsule ( 60 mg ) three time day alone combination bortezomib , 168 day .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients disease progression Day 73 Study B003 patient fully understand element , sign date , write Informed Consent Form ( ICF ) initiation protocolspecified procedure Patients active uncontrolled infection condition , include laboratory abnormality , opinion investigator place patient unacceptable risk participate study pregnant lactate woman , use adequate contraception sexually active woman childbearing potential ( WCBP ) agree use least two form medically accept birth control , include one barrier method , duration study men agree use acceptable method contraception throughout study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>SCIO-469</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>p38 MAP kinase</keyword>
</DOC>